India’s cancer drug price reset enters its final week with a discrepancy that patients and buyers should understand before November 9, 2026. The National Pharmaceutical Pricing Authority (NPPA) has been updating its revised maximum retail price (MRP) schedule for non-scheduled anti-cancer medicines in rolling instalments — and the headline count the regulator cites publicly is now well below the number of itemised product entries actually on the list.
As of the update incorporating company submissions received up to November 3, 2026, the NPPA’s public position is that the list covers 1,085 anti-cancer medicines across brands. An itemised analysis of the same schedule, published by DrugsControl Media Services on November 5, 2026, counts 1,136 product entries — of which 946 carry MRP reductions and 190 remain unchanged.
📊 Why the Official Count and the Itemised Count Differ
This is the same counting problem that has dogged the entire trade margin rationalisation exercise since it began, and it is not evidence that either figure is wrong. The two numbers count different units:
- 137 — the number of molecules identified in the NPPA’s October 17, 2026 notification for trade margin rationalisation. This is the authoritative scope of the policy.
- 1,085 — the regulator’s own running count of anti-cancer medicines across brands in the revised list, as stated in its public updates.
- 1,136 — the number of product entries (specific brand, strength and pack combinations) itemised in the schedule as published on November 5.
A single molecule marketed by several companies, in multiple strengths and pack sizes, generates many product entries. That arithmetic explains why the itemised list is longer than the headline count, and why earlier coverage of the same order simultaneously reported 543 brands and 643 brand entries at different points in the rollout.
📅 How the List Has Grown — A Week-by-Week Timeline
- October 17, 2026 — NPPA notifies trade margin rationalisation for 137 non-scheduled anti-cancer drugs under Paragraph 19 of the Drugs (Prices Control) Order, 2013, capping the aggregate trade margin at 30% of MRP.
- October 28, 2026 — First large tranche published: MRPs revised downward for 543 anti-cancer medicines of different brands, effective November 9.
- October 30, 2026 — An analysis of 643 listed packs finds an average cut of 38.22%, but 159 entries unchanged — roughly one in four packs, including several high-cost patented therapies.
- November 3–4, 2026 — NPPA updates the list to 1,085 medicines, reflecting company submissions up to November 3. The regulator states the list will keep updating as more manufacturers file revised prices.
- November 5, 2026 — Itemised count of the published schedule reaches 1,136 product entries: 946 reduced, 190 unchanged.
The direction of travel is clear: the list is a moving target that expands as companies comply, which means a price check done today may not match the schedule next week.
⚠️ The Unchanged 190: What Buyers Must Not Assume
The single most consequential detail for anyone sourcing oncology medicines is that a substantial slice of the list shows no price reduction at all. In the October 30 analysis, the unchanged entries included high-cost patented therapies — Keytruda (pembrolizumab) 100 mg injection at about ₹2.16 lakh, Tagrisso (osimertinib) 80 mg 30 tablets at about ₹4.16 lakh, Alecensa (alectinib) 150 mg 224 capsules at about ₹4.3 lakh, Voranigo (vorasidenib) 40 mg 30 tablets at about ₹6 lakh, and Koselugo (selumetinib) 25 mg 60 capsules at over ₹10 lakh, as reported by The Economic Times.
The practical implication: the November 9 reset is not a uniform discount on cancer treatment. The deepest cuts fall on packs where trade margins were most inflated. Where a product was already priced close to the manufacturer’s sale price, or where margins were never the main component of the retail price, the MRP barely moves. Buyer expectations set on the “up to 70% cheaper” headline will be disappointed on roughly one entry in six.
🧮 The Mechanism in One Paragraph: 30% of MRP Is Not a 30% Cut
The aggregate trade margin is capped at 30% of MRP, which is arithmetically equivalent to a 42.86% markup over the manufacturer’s sale price. Patient advocates, including Supreme Court petitioner KC Jain, have argued this still permits retailer and stockist margins higher than what the existing DPCO framework contemplates for scheduled drugs, where the retailer margin is capped at 16% of the price to retailer. That argument is the substance of the litigation now running alongside the price cuts, and it is the reason the November 9 list should be read as a floor on regulatory action rather than a final settlement.
✅ A Practical Checklist for Buyers Before November 9
- Check the specific pack, not the molecule. The new price attaches to a brand-strength-pack combination. Confirm the exact pack configuration on your invoice against the schedule entry.
- Verify the entry is on the list at all. With 190 entries unchanged in the itemised schedule, absence of a reduction does not mean a seller is overcharging — it may mean the product is not covered or was already compliant.
- Do not accept a post-dated invoice. Prices effective November 9 should not be billed on stock supplied before that date at the new rate, nor should pre-November stock be sold forward at rates above the new MRP after it takes effect.
- Re-check the schedule in the week after November 9. The NPPA has explicitly stated the list will continue to be revised as manufacturers submit data.
- Source only through licensed, verifiable channels. Price caps do not substitute for supply-chain due diligence. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📌 What IMSDA Is Watching Next
Three developments will determine whether the November 9 reset delivers on its stated intent:
- Compliance density — how many of the 190 unchanged entries convert to reductions once remaining manufacturers file their data.
- Hospital billing behaviour — margin compression at the retail level only translates into patient savings if hospital and pharmacy billing follows the new MRP.
- The Supreme Court’s position — the broader margin-structure challenge, if it goes against the current 30% formula, would require a second repricing round.
Sources
DrugsControl Media Services, November 5, 2026 — itemised count of the revised MRP schedule (1,136 product entries; 946 reductions; 190 unchanged). The Hindu BusinessLine and The Economic Times / PTI, November 3–4, 2026 — NPPA update to 1,085 medicines, company submissions up to November 3, effective November 9. The Economic Times, October 30, 2026 — analysis of 643 listed packs, average cut 38.22%, 159 entries unchanged, named patented product MRPs, KC Jain commentary. NPPA notification, October 17, 2026 — trade margin rationalisation for 137 non-scheduled anti-cancer drugs under Paragraph 19 of the DPCO, 2013, aggregate trade margin capped at 30% of MRP.
This article is regulatory and market information for trade and patient-awareness purposes. It is not medical advice. Treatment decisions, including choice of oncology regimen and sourcing, must be made with a qualified oncologist.
For more information, contact IMSDA at contact@indiamedicine.org.